The complaint filed by law firm Berger Montague alleges that Menlo Park-based GRAIL misled shareholders regarding its NHS-Galleri cancer detection trial. According to the suit, the company failed to disclose that the study’s design was insufficient to reach its primary objective—a statistically significant reduction in Stage III-IV cancer diagnoses. Furthermore, the firm claims defendants withheld top-line results that hinted at adverse trends and the necessity for a much longer follow-up period.

Market reaction was swift when the truth emerged. On February 19, 2026, GRAIL admitted the trial failed its primary endpoint and conceded that extended observation was required. Shares plummeted from $101.53 to $50.21, erasing over 50% of the company's value in a single session. Investors seeking to participate in the class action may reach out to Andrew Abramowitz or Caitlin Adorni at Berger Montague to discuss their legal standing.